Not to nitpick too much, and not sure how importan

Not to nitpick too much, and not sure how important are these little inconsistencies (maybe is a fluid situation with changing events), but did anyone else hear NP on video today say that nobody has proven mortality benefit in randomized controlled trial? If this is an exaggeration, it doesn't help our cause at all.

As far as I know, dexamethasone was shown to have mortality benefit in large UK study (for those on oxygen, but not for those without any respiratory support), and so did itolizumab in small Indian study, right? Both of these were randomized placebo controlled clinical trials. Maybe he is quibbling about these both being open label, but leronlimab study is blinded.

In any event, we would be in very rare company.

Even in ARDS, I think there has only been one RCT showing mortality benefit, from ATHX.

https://www.globenewswire.com/news-release/20...ID-19.html

https://www.sciencemag.org/news/2020/06/cheap...9-patients

https://www.nejm.org/doi/full/10.1056/NEJMoa2021436

We'll see if lenzilumab, VIP, convalescent plasma, anti-SARS2 antibodies, stem cell immunomodulatory treatments, or any other therapies have any mortality benefit, too.